It's another drug, but a Brazilian Albert Einstein
Post# of 148161
https://www.medpagetoday.com/infectiousdiseas...ate_active
Same principal investigator as ours.
In this study, Xeljanz, a JAK inhibitor, decreased high-flow oxygen (non-intubated) patients' "death or respiratory failure" from 29% to 18%.